POST Online Media Lite Edition



 

France fine Novartis, Roche and Genentech $500 million

Christian Fernsby |
The French competition authority (AFC) on Thursday slapped a record 444 million euro ($500 million) fine on pharma groups Novartis, Roche and Genentech over market abuses in sales of macular degeneration drugs.

Topics: FRANCE    NOVARTIS    ROCHE    GENENTECH   

The trio were found to have abused dominant market position to sell their Lucentis drug, developed by US firm Genentech and used in the treatment of age-related macular degeneration (AMD), to the detriment of another much cheaper treatment, Avastin.

Swiss firm Novartis marketed Lucentis outside the US. But doctors realised that Genentech’s anti-cancer drug Avastin could have positive effects on the eye disease and began to prescribe it.

Roche, which, since 2009, has a 100 percent capital stake in Genentech, markets Avastin outside of the United States.

An injection of Avastin costs around 30 to 40 euros, compared with a launch price of 1,161 euros for Lucentis ramping up the cost for French social security, which picks up the full tab for the treatment needed by some 150,000 people in France.


What to read next

Novartis Pharmaceuticals to pay $4.4 million to resolve medicaid fraud allegations
Romanian Competition Council sanctioned Roche Romania with fine of 12,8 million euros
South Korea to halt benefits to Novartis, fines it $49.5 million